Rheumatoid arthritis patients who took anti-tumor necrosis factor drugs such as etanercept, infliximab and adalimumab had a significantly greater risk of developing shingles than those on disease-modifying antirheumatic drugs, according to a study of more than 15,000 patients in the U.K. The findings appeared in the journal Annals of the Rheumatic Diseases.

Related Summaries